Erythropoietin in neonatal brain protection: the past, the present and the future.
Over the last decade, neuroprotective effects of erythropoietin (Epo) and its underlying mechanisms in terms of signal transduction pathways have been defined and there is a growing interest in the potential therapeutic use of Epo for neuroprotection. Several mechanisms by which Epo provides neuroprotection are recognized. In this review, we focused on the neuroprotective mechanisms of Epo and provide a short overview on both experimental and clinical studies, testing Epo as a neuroprotective agent in the neonatal brain injury, and the safety concerns with the clinical use of Epo treatment in neonates.
Department of Pediatrics, Division of Neonatology, School of Medicine, Dokuz Eylul University, Izmir, Turkey. abdullah.kumral@deu.edu.tr
Abdullah
A
Kumral
Funda
F
Tüzün
Meryem Gülfer
MG
Oner
Sermin
S
Genç
Nuray
N
Duman
Hasan
H
Ozkan
D001812:Blood-Brain Barrier / Q000378:metabolism; D001930:Brain Injuries / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D009457:Neuroglia / Q000378:metabolism; D009474:Neurons / Q000378:metabolism; D018696:Neuroprotective Agents / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology
D018696:Neuroprotective Agents; D004921:Erythropoietin